Patents Assigned to Wellstat Biologics Corporation
-
Patent number: 9844574Abstract: Mammalian subjects having a neoplasm are treated with a virus and a camptothecin compound, for example irinotecan or topotecan. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus. The treatment can also include administration of a monoclonal antibody against epidermal growth factor receptor, for example cetuximab.Type: GrantFiled: June 28, 2016Date of Patent: December 19, 2017Assignee: Wellstat Biologics CorporationInventors: Robert M Lorence, Michael Scot Roberts
-
Publication number: 20140065140Abstract: Mammalian subjects having a neoplasm are treated with a virus and a camptothecin compound, for example irinotecan or topotecan. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus. The treatment can also include administration of a monoclonal antibody against epidermal growth factor receptor, for example cetuximab.Type: ApplicationFiled: November 11, 2013Publication date: March 6, 2014Applicant: Wellstat Biologics CorporationInventors: Robert M. LORENCE, Michael Scot ROBERTS
-
Patent number: 8557531Abstract: Endothelial cells are detected in a blood sample by enriching the endothelial cells from the blood sample followed by performing on the enriched endothelial cells an immunoassay capable of detecting antigens expressed by the endothelial cells. The immunoassay is capable of detecting antigen expressed from 300 endothelial cells per milliliter of blood. The method can be used for assaying mature circulating endothelial cells or circulating endothelial progenitor cells.Type: GrantFiled: April 18, 2007Date of Patent: October 15, 2013Assignee: Wellstat Biologics CorporationInventor: Robert M. Lorence
-
Patent number: 8282917Abstract: The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.Type: GrantFiled: March 30, 2010Date of Patent: October 9, 2012Assignees: Wellstat Biologics Corporation, Ottawa Hospital Research InstituteInventors: John C. Bell, Brian D. Lichty, David F. Stodjl
-
Patent number: 8147822Abstract: The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility is more pronounced in the presence of interferon. The tumor cell is characterized by having low levels, or no, PKR activity, or as being PKR?/?, STAT1?/? or both PKR?/? and STAT1?/?. The virus is selected from the group consisting of Rhabdovirus and picornavirus, and preferably is vesicular stomatitis virus (VSV) or a derivative thereof.Type: GrantFiled: September 18, 2000Date of Patent: April 3, 2012Assignee: Wellstat Biologics CorporationInventors: John C. Bell, Nahum Sonenberg, David F. Stojdl, Earl G. Brown, Harold L. Atkins, Ricardo M. Marius, Brian D. Lichty, Shane B. Knowles
-
Patent number: 8137663Abstract: A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic virus.Type: GrantFiled: March 26, 2009Date of Patent: March 20, 2012Assignee: Wellstat Biologics CorporationInventors: William S. Groene, Jeffrey A. Miller, Stephen N. Mueller
-
Patent number: 8105578Abstract: The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.Type: GrantFiled: January 29, 2007Date of Patent: January 31, 2012Assignee: Wellstat Biologics CorporationInventors: Michael S. Roberts, Robert M. Lorence, William S. Groene, Harvey Rabin, Reid W. von Borstel
-
Patent number: 8043612Abstract: The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.Type: GrantFiled: November 18, 2008Date of Patent: October 25, 2011Assignee: Wellstat Biologics CorporationInventors: Michael S. Roberts, Robert M. Lorence, William S. Groene, Harvey Rabin, Reid W. von Borstel
-
Patent number: 8012480Abstract: The protein EGFR, ERCC1, RRM1, thymidylate synthase, or beta-tubulin from cancer cells is detected in a blood sample by enriching the cancer cells from the blood sample followed by performing on the enriched cancer cells an immunoassay capable of detecting the proteins mentioned above. Cancer patients overexpressing EGFR are treated with an anti-EGFR agent, for example cetuximab, panitumumab, erlotinib or gefitinib.Type: GrantFiled: April 18, 2007Date of Patent: September 6, 2011Assignee: Wellstat Biologics CorporationInventor: Robert M. Lorence
-
Publication number: 20110117060Abstract: Mammalian subjects having a neoplasm are treated with a virus, a fluoropyrimidine, for example 5-fluorouracil, and a camptothecin compound. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus.Type: ApplicationFiled: July 20, 2010Publication date: May 19, 2011Applicant: WELLSTAT BIOLOGICS CORPORATIONInventors: Robert M. Lorence, Michael S. Roberts
-
Patent number: 7932290Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed.Type: GrantFiled: August 31, 2009Date of Patent: April 26, 2011Assignee: Wellstat Biologics CorporationInventors: Kirvin L. Hodge, Shalini Sharma, Albert C. Lee, Reid W. von Borstel
-
Patent number: 7914979Abstract: Envelope viruses (e.g. Newcastle disease virus (NDV)) are formulated for storage at moderately cold temperatures (e.g. ?20° C.). The formulation is an aqueous solution containing the enveloped virus at a concentration of from 106 PFU/mL to 1012 PFU/mL; and a non-reducing saccharide (e.g. sucrose). When the non-reducing saccharide is a disaccharide it is present in the solution at a concentration of from 5% (w/v) to 50% (w/v), and when it is a monosaccharide it is present in the solution at a concentration of from 2.5% (w/v) to 25% (w/v). The solution has an osmotic pressure of about 250 mOs or higher, and has a pH of from 5 to 10.Type: GrantFiled: November 4, 2005Date of Patent: March 29, 2011Assignee: Wellstat Biologics CorporationInventors: Tzer-Fen Chen, Jouhn-Wern Jang, Jeffrey A. Miller
-
Publication number: 20110070598Abstract: The expression of Her-2/neu protein on circulating cancer cells in a blood sample is detected by isolating the cancer cells from the blood sample and then performing on the isolated cancer cells a sensitive Her-2/neu immunoassay. A positive result indicates the expression of Her-2/neu on cancer cells in the blood sample. This method can be used to identify cancer patients who are likely to benefit from treatment with an anticancer agent that targets Her-2/neu, such as trastuzumab (HERCEPTIN).Type: ApplicationFiled: February 18, 2010Publication date: March 24, 2011Applicant: WELLSTAT BIOLOGICS CORPORATIONInventors: Robert M. Lorence, Ming Lu
-
Patent number: 7780962Abstract: The subject invention relates to viruses that are able to replicate and thereby kill neoplastic cells with a deficiency in the IFN-mediated antiviral response, and their use in treating neoplastic disease including cancer and large tumors. RNA and DNA viruses are useful in this regard. The invention also relates to methods for the selection, design, purification and use of such viruses for cancer therapy.Type: GrantFiled: June 13, 2002Date of Patent: August 24, 2010Assignee: Wellstat Biologics CorporationInventors: Michael S. Roberts, Robert M. Lorence, William S. Groene, Harvey Rabin, Reid W. von Borstel
-
Patent number: 7767200Abstract: Mammalian subjects having a neoplasm are treated with a virus, a fluoropyrimidine, for example 5-fluorouracil, and a camptothecin compound. The virus is selected from the group consisting of a Newcastle disease virus, a measles virus, a vesicular stomatitis virus, an influenza virus, a Sindbis virus, a picornavirus, and a myxoma virus.Type: GrantFiled: July 12, 2006Date of Patent: August 3, 2010Assignee: Wellstat Biologics CorporationInventors: Robert M. Lorence, Michael S. Roberts
-
Patent number: 7736640Abstract: The invention provides a method of treating cancer in a mammal comprising administering to the mammal an effective amount of virus, particularly Newcastle Disease Virus or other Paramyxovirus. The invention also provides a method of treating cancer in a mammal comprising administering such viruses to the mammal in combination with another agent such as a chemotherapeutic compound, immunoadjuvant, cytokine, or immunosuppressive agent. The invention further provides a method of detecting cancer cells in a mammal using Paramyxovirus as an imaging agent and as an indicator of cancer cell growth in the mammal. The invention further provides genetically engineered Paramyxoviruses, and kits containing the viral compositions disclosed by the invention.Type: GrantFiled: May 26, 2006Date of Patent: June 15, 2010Assignee: Wellstat Biologics CorporationInventors: Robert M. Lorence, Kirk W. Reichard
-
Patent number: 7731974Abstract: The present invention provides mutant viruses with a decreased ability to block nuclear transport of mRNA or protein in an infected cell which are attenuated in vivo. The mutant viruses of the present invention may also be capable of triggering the anti-viral systems of normal host cells while remaining sensitive to the effects of these systems. The present invention further provides for the use of the mutant viruses in a range of applications including, but not limited to, as therapeutics for the treatment of cancer and infections, as vaccines and adjuvants, as viral vectors, and as oncolytic and cytolytic agents for the selective lysis of malignant or infected cells.Type: GrantFiled: March 29, 2004Date of Patent: June 8, 2010Assignees: Ottawa Hospital Research Institute, Wellstat Biologics CorporationInventors: John C. Bell, Brian D. Lichty, David F. Stojdl
-
Publication number: 20100120072Abstract: The expression of Her-2/neu protein on circulating cancer cells in a sample of blood or peripheral blood mononuclear cells (PBMCs) is detected by performing a sensitive Her-2/neu immunoassay. There is no need to isolate the cancer cells before performing the immunoassay. A positive result indicates the expression of Her-2/neu on cancer cells in the blood sample.Type: ApplicationFiled: April 15, 2008Publication date: May 13, 2010Applicant: WELLSTAT BIOLOGICS CORPORATIONInventors: Robert M. Lorence, Ming Lu
-
Publication number: 20090317362Abstract: The present invention relates to therapeutic use of Myxoma virus. Myxomas virus can selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon and can be used to treat diseases characterized by the presence of such cells, including cancer.Type: ApplicationFiled: August 28, 2009Publication date: December 24, 2009Applicant: WELLSTAT BIOLOGICS CORPORATIONInventors: Grant McFadden, John C. Bell
-
Publication number: 20090291920Abstract: The expression of a steroid receptor from circulating carcinoma cells in a blood sample is detected by isolating the carcinoma cells from the blood sample, making an extract from the isolated carcinoma cells and then performing on the extract a sensitive immunoassay capable of detecting the carcinoma cell-associated steroid receptor. A positive result indicates the presence of the steroid receptor in the carcinoma cells. This method can be used to identify cancer patients who are likely to benefit from treatment with an endocrine therapeutic agent.Type: ApplicationFiled: April 18, 2007Publication date: November 26, 2009Applicant: WELLSTAT BIOLOGICS CORPORATIONInventors: Ming Lu, Robert M. Lorence